Home › Prostate Cancer › Pennsylvania › Lancaster
Prostate Cancer clinical trials in Lancaster, PA
4 studies for Prostate Cancer are looking for participants at sites in and around Lancaster (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
RecruitingPhase 3
- The Centers for Advanced Urology d/b/a Keystone Urology Specialist, Lancaster
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
RecruitingPhase 3
- Research Site, Lancaster
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
RecruitingPhase 2
- Lancaster Urology, Lancaster
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
RecruitingPhase 1
- Keystone Urology Specialists, Lancaster
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY103 studies
- Houston, TX76 studies
- Los Angeles, CA61 studies
- Boston, MA59 studies
- St. Louis, MO46 studies
- Chicago, IL45 studies
- San Francisco, CA45 studies
- Philadelphia, PA44 studies
- Baltimore, MD43 studies
- Nashville, TN42 studies
- Seattle, WA42 studies
- Washington, DC38 studies
Other studies in Lancaster
- Non-Small Cell Lung Cancer7 studies
- Heart Failure5 studies
- Cardiovascular Disease5 studies
- Metastatic Cancer4 studies
- Breast Cancer4 studies
- Lung Cancer3 studies
- Bladder Cancer3 studies
- Amblyopia3 studies
- Heart Diseases3 studies
- Non-Muscle Invasive Bladder Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.